Development of a novel combination tablet containing trimebutine maleate and Mosapride citrate (cas 112885-42-4) for the treatment of functional dyspepsia
-
Add time:07/31/2019 Source:sciencedirect.com
To develop a novel combination tablet which contained 100 mg trimebutine maleate and 5 mg Mosapride citrate (cas 112885-42-4) (TMCT) for the treatment of functional dyspepsia, the wet granulation method was used to prepare TMCTs with various amounts of diluents and stabilizers. The levels of impurities, the stability and the dissolution of the TMCTs were investigated. The oral bioavailability of drugs in the TMCTs was then evaluated and compared to the simultaneous oral administration of trimebutine maleate-loaded and mosapride citrate-loaded commercial products in the beagle dog. Among the diluents tested, d-mannitol was selected, since the microcrystalline cellulose and lactose did not inhibit the production of drug impurities due to their hygroscopic properties and chemical interactions, respectively. Furthermore, succinic acid was selected as the stabilizer because it gave the lowest level of total drug impurities of the organic acids tested. The combination tablet of trimebutine maleate and mosapride citrate prepared with D-mannitol and succinic acid gave a total drug content higher than 95% and total impurities lower than 0.5% at 25 °C/60% RH and 40 °C/75% RH during a 6-month period, indicating that the tablets were stable for at least 6 months. Furthermore, this combination tablet showed a similar dissolution to the trimebutine maleate-loaded and mosapride citrate-loaded commercial products and gave insignificantly different absorption compared to these commercial products in beagle dogs. Thus, the combination tablet of trimebutine maleate and mosapride citrate prepared with d-mannitol and succinic acid would be a stable and effective oral pharmaceutical product for the treatment of functional dyspepsia.
We also recommend Trading Suppliers and Manufacturers of Mosapride citrate (cas 112885-42-4). Pls Click Website Link as below: cas 112885-42-4 suppliers
Prev:Spectrophotometric determination of carbamazepine and Mosapride citrate (cas 112885-42-4) in pure and pharmaceutical preparations
Next:Dual Role of Mosapride citrate (cas 112885-42-4) Hydrate on the Gastric Emptying Evaluated by the Breath Test in Conscious Rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effect of Mosapride citrate (cas 112885-42-4) Hydrate on the Colon Cleansing Action of Polyethylene Glycol Electrolyte Lavage Solution (PEG-ELS) in Guinea Pigs08/04/2019
- Liquid chromatography–tandem mass spectrometric method for determination of Mosapride citrate (cas 112885-42-4) in equine tissues08/03/2019
- Effects of Mosapride citrate (cas 112885-42-4), a 5-HT4–Receptor Agonist, on Gastric Distension–Induced Visceromotor Response in Conscious Rats08/02/2019
- Dual Role of Mosapride citrate (cas 112885-42-4) Hydrate on the Gastric Emptying Evaluated by the Breath Test in Conscious Rats08/01/2019
- Spectrophotometric determination of carbamazepine and Mosapride citrate (cas 112885-42-4) in pure and pharmaceutical preparations07/30/2019
- Dose-dependent effects of Mosapride citrate (cas 112885-42-4) on duodenal and cecal motility in donkeys (Equus asinus)07/29/2019
- The effect of Mosapride citrate (cas 112885-42-4) on constipation in patients with diabetes07/28/2019
- Comparison of the effects of esomeprazole plus Mosapride citrate (cas 112885-42-4) and botulinum toxin A on vocal process granuloma07/27/2019
- Molecularly imprinted polymers based biomimetic sensors for Mosapride citrate (cas 112885-42-4) detection in biological fluids07/26/2019
-
Health and Chemical more >
-
Related Products